Skip to main content
. 2018 Sep 5;68(10):1725–1732. doi: 10.1093/cid/ciy753

Table 2.

Human Immunodeficiency Virus-1–specific Antibody Levels at Baseline With Antibody Decay Rates

Antibody Specificity Baselinea Ab Decay Rate, as Units/Months With 95% CIb Age at Clearance-SR, in Monthsc Age at Clearance- ET-R, in Monthsc
SR ET-R LT-R NR SR ET-R LT-R NR Compared to SR (Reference)
gp160 log, ug/ml 1.8
(1.2–2.2)		 1.5
(0.9–1.6)		 1.6
(0.7–1.9)		 1.4
(1.0–1.7)		 -0.19
(-0.22, -0.16)		 -0.18
(-0.21, -0.15)		 -0.04
(-0.05, -0.02)		 -0.003
(-0.03, 0.02)		 ET P = .91
LT P < .001
NR P < .001		 12.4 12.4
RT
log, ug/ml		 1.5
(0.6–1.6)		 1.4
(0.3–1.5)		 -0.7
(-0.7–1.7)		 0.5
(-0.05–1.2)		 -0.14
(-0.17, -0.11)		 -0.15
(-0.20, -0.10)		 -0.05
(-0.09, -0.01)		 0.005
(-0.02, 0.03)		 ET P = .87
LT P < .001
NR P < .001		 12.7 12.9
gp41
log, ug/ml		 3.2
(2.5–3.5)		 2.2
(1.87–2.7)		 2.1
(1.6–2.6)		 2.4
(1.6–2.8)		 -0.25
(-0.28, -0.21)		 -0.22
(-0.26, -0.18)		 -0.04
(-0.06,-0.02)		 -0.003
(-0.03, 0.03)		 ET P = .53
LT P < .001
NR P < .001		 12.8 12.2
p24
log, ug/ml		 1.6
(0.61–2.1)		 1.9
(1.7–2.2)		 1.4
(0.4–1.7)		 1.7
(1.1–1.9)		 -0.17
(-0.19, -0.14)		 -0.14
(-0.18, -0.11)		 -0.04
(-0.07,-0.01)		 0.02
(0.00, 0.05)		 ET P = .24
LT P < .001
NR P < .001		 12.9 20.6
p31, OD 1.5
(1.4–1.6)		 1.3
(0.8–1.5)		 0.4
(0.3–1.5)		 0.9
(0.4–1.5)		 -0.09
(-0.10, -0.07)		 -0.08
(-0.10, -0.06)		 -0.01
(-0.03, 0.00)		 0.008
(-0.01, 0.03)		 ET P = .80
LT P < .001
NR P < .001		 11.7 11.6
p17, OD 1.2
(0.4–1.9)		 0.9
(0.4–1.1)		 0.5
(0.3–0.8)		 0.9
(0.3–1.4)		 -0.08
(-0.10, -0.06)		 -0.04
(-0.07, -0.02)		 -0.03
(-0.04, -0.01)		 0.005
(-0.01, 0.02)		 ET P = .01
LT P < .001
NR P < .001		 10.9 16.6

Abbreviations: Ab, antibody; CI, confidence interval; ET, early therapy; LT, late therapy; NR, viral non-responders; OD, optical densities; R, viral responders; SR, seroreverters; RT, reverse transcriptase.

aMedian with interquartile range.

bSlopes with 95% CIs.

cEstimate based on linear regression model parameters.